Dr. Buas’ primary research focus is the molecular/genetic epidemiology of esophageal adenocarcinoma (EAC) and its precursor lesion, Barrett’s esophagus (BE). As such, Dr. Buas designs and leads studies investigating the role of inherited genetics in the etiology of BE/EAC using a combination of statistical, computational, and experimental approaches. These include targeted and genome-wide discovery scans to identify novel genetic susceptibility loci; multi-omics informatics pipelines to prioritize single nucleotide variants based on estimated regulatory potential; and laboratory-based functional assays to validate and characterize candidate functional/causal variants, gene targets, and disease pathways. A second area of interest is the identification of novel molecular signatures and biomarkers of esophageal and ovarian cancers using high-throughput omics profiling technologies.The long-term translational goal of Dr. Buas’ research is to advance new strategies for cancer prevention, risk assessment, and early detection. His work is supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Cancer Institute (NCI).